Pharmacology of mitoxantrone in cancer patients

Niramol Savaraj, Katherine Lu, Valdivieso Manuel, Ti Li Loo

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Radioactive mitoxantrone was administered at doses of 1-12 mg/m2 by rapid IV infusion to 11 patients. Of the 11 patients, six had normal liver and kidney function tests while the remaining five had abnormal third space and/or hepatic dysfunction. In the former group, the initial t1/2 was 13.7 min and terminal t1/2 was 37.4 h. The apparent volume of distribution was 13.8 l/kg. The total clearance rate was 230.7 ml/kg/h. The recovery of unchanged mitoxantrone from urine was 6.8% at 24 h and 7.3% at 72 h, while the corresponding recovery of total radioactivity was 9.4% at 24 h and 11.3% at 72 h. In the five patients with abnormal liver function or third space the initial t1/2 was variable and ranged from 11.5-63.6 min, and the terminal t1/2 ranged from 53.3-173.2 h, whereas the total clearance rate varied from 52.7-170.2 ml/kg/h. However, the cumulative urinary excretion of unchanged mitoxantrone was similar to that of patients with normal hepatic function: 3.9 at 24 h and 5 at 72 h. Biliary excretion was studied in one of these patients, who had jaundice and hepatic impairment; only 2.3% of 14C was excreted in 24 h and 2.7% in 96 h, of which 39% and 41%, respectively, were unchanged mitoxantrone. Our results suggest that mitoxantrone is taken up rapidly by tissue from which it is released slowly. Reduction of mitoxantrone dose is therefore advisable in patients with liver dysfunction or abnormal third space.

Original languageEnglish
Pages (from-to)113-117
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume8
Issue number1
DOIs
StatePublished - Apr 1 1982
Externally publishedYes

Fingerprint

Mitoxantrone
Pharmacology
Liver
Neoplasms
Kidney Function Tests
Recovery
Liver Function Tests
Radioactivity
Jaundice
Liver Diseases
Urine
Tissue

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Pharmacology of mitoxantrone in cancer patients. / Savaraj, Niramol; Lu, Katherine; Manuel, Valdivieso; Loo, Ti Li.

In: Cancer Chemotherapy and Pharmacology, Vol. 8, No. 1, 01.04.1982, p. 113-117.

Research output: Contribution to journalArticle

Savaraj, Niramol ; Lu, Katherine ; Manuel, Valdivieso ; Loo, Ti Li. / Pharmacology of mitoxantrone in cancer patients. In: Cancer Chemotherapy and Pharmacology. 1982 ; Vol. 8, No. 1. pp. 113-117.
@article{99316426d1f74a46aab150b02779ca3d,
title = "Pharmacology of mitoxantrone in cancer patients",
abstract = "Radioactive mitoxantrone was administered at doses of 1-12 mg/m2 by rapid IV infusion to 11 patients. Of the 11 patients, six had normal liver and kidney function tests while the remaining five had abnormal third space and/or hepatic dysfunction. In the former group, the initial t1/2 was 13.7 min and terminal t1/2 was 37.4 h. The apparent volume of distribution was 13.8 l/kg. The total clearance rate was 230.7 ml/kg/h. The recovery of unchanged mitoxantrone from urine was 6.8{\%} at 24 h and 7.3{\%} at 72 h, while the corresponding recovery of total radioactivity was 9.4{\%} at 24 h and 11.3{\%} at 72 h. In the five patients with abnormal liver function or third space the initial t1/2 was variable and ranged from 11.5-63.6 min, and the terminal t1/2 ranged from 53.3-173.2 h, whereas the total clearance rate varied from 52.7-170.2 ml/kg/h. However, the cumulative urinary excretion of unchanged mitoxantrone was similar to that of patients with normal hepatic function: 3.9 at 24 h and 5 at 72 h. Biliary excretion was studied in one of these patients, who had jaundice and hepatic impairment; only 2.3{\%} of 14C was excreted in 24 h and 2.7{\%} in 96 h, of which 39{\%} and 41{\%}, respectively, were unchanged mitoxantrone. Our results suggest that mitoxantrone is taken up rapidly by tissue from which it is released slowly. Reduction of mitoxantrone dose is therefore advisable in patients with liver dysfunction or abnormal third space.",
author = "Niramol Savaraj and Katherine Lu and Valdivieso Manuel and Loo, {Ti Li}",
year = "1982",
month = "4",
day = "1",
doi = "10.1007/BF00292881",
language = "English",
volume = "8",
pages = "113--117",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Pharmacology of mitoxantrone in cancer patients

AU - Savaraj, Niramol

AU - Lu, Katherine

AU - Manuel, Valdivieso

AU - Loo, Ti Li

PY - 1982/4/1

Y1 - 1982/4/1

N2 - Radioactive mitoxantrone was administered at doses of 1-12 mg/m2 by rapid IV infusion to 11 patients. Of the 11 patients, six had normal liver and kidney function tests while the remaining five had abnormal third space and/or hepatic dysfunction. In the former group, the initial t1/2 was 13.7 min and terminal t1/2 was 37.4 h. The apparent volume of distribution was 13.8 l/kg. The total clearance rate was 230.7 ml/kg/h. The recovery of unchanged mitoxantrone from urine was 6.8% at 24 h and 7.3% at 72 h, while the corresponding recovery of total radioactivity was 9.4% at 24 h and 11.3% at 72 h. In the five patients with abnormal liver function or third space the initial t1/2 was variable and ranged from 11.5-63.6 min, and the terminal t1/2 ranged from 53.3-173.2 h, whereas the total clearance rate varied from 52.7-170.2 ml/kg/h. However, the cumulative urinary excretion of unchanged mitoxantrone was similar to that of patients with normal hepatic function: 3.9 at 24 h and 5 at 72 h. Biliary excretion was studied in one of these patients, who had jaundice and hepatic impairment; only 2.3% of 14C was excreted in 24 h and 2.7% in 96 h, of which 39% and 41%, respectively, were unchanged mitoxantrone. Our results suggest that mitoxantrone is taken up rapidly by tissue from which it is released slowly. Reduction of mitoxantrone dose is therefore advisable in patients with liver dysfunction or abnormal third space.

AB - Radioactive mitoxantrone was administered at doses of 1-12 mg/m2 by rapid IV infusion to 11 patients. Of the 11 patients, six had normal liver and kidney function tests while the remaining five had abnormal third space and/or hepatic dysfunction. In the former group, the initial t1/2 was 13.7 min and terminal t1/2 was 37.4 h. The apparent volume of distribution was 13.8 l/kg. The total clearance rate was 230.7 ml/kg/h. The recovery of unchanged mitoxantrone from urine was 6.8% at 24 h and 7.3% at 72 h, while the corresponding recovery of total radioactivity was 9.4% at 24 h and 11.3% at 72 h. In the five patients with abnormal liver function or third space the initial t1/2 was variable and ranged from 11.5-63.6 min, and the terminal t1/2 ranged from 53.3-173.2 h, whereas the total clearance rate varied from 52.7-170.2 ml/kg/h. However, the cumulative urinary excretion of unchanged mitoxantrone was similar to that of patients with normal hepatic function: 3.9 at 24 h and 5 at 72 h. Biliary excretion was studied in one of these patients, who had jaundice and hepatic impairment; only 2.3% of 14C was excreted in 24 h and 2.7% in 96 h, of which 39% and 41%, respectively, were unchanged mitoxantrone. Our results suggest that mitoxantrone is taken up rapidly by tissue from which it is released slowly. Reduction of mitoxantrone dose is therefore advisable in patients with liver dysfunction or abnormal third space.

UR - http://www.scopus.com/inward/record.url?scp=0020033265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020033265&partnerID=8YFLogxK

U2 - 10.1007/BF00292881

DO - 10.1007/BF00292881

M3 - Article

C2 - 7094196

AN - SCOPUS:0020033265

VL - 8

SP - 113

EP - 117

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -